ABSTRACT
OBJECTIVE: This meta-analysis aimed to assess the effects of crocin supplementation on fasting blood glucose (FBG) and lipid profile levels in clinical trial studies. DESIGN: A systematic literature search was performed in PubMed, Scopus, Embase, Web of Science, and the Cochrane Library databases for clinical trials published from the beginning up to November 2019. Of the 547 papers identified from all searched databases, eight eligible studies with nine effect sizes have all needed criteria for inclusion in this meta-analysis. RESULTS: Results of the pooled random-effect size analysis showed just a significant decreasing effect of crocin supplementation on FBG (WMD: -6.52â¯mg/l, 95 % CI, -11.96, -1.08; pâ¯=â¯0.019) and TC (WMD: -4.64â¯mg/l, 95 % CI, -8.19, -1.09; pâ¯=â¯0.010). Crocin supplements did not have any significant effect on serum TG (pâ¯=â¯0.144) levels, LDL-C (pâ¯=â¯0.161), and HDL-C (pâ¯=â¯0.872) levels. Results showed that crocin supplementation could beneficially have effect on TG level only when trial duration less than 12 weeks and LDL-C levels in trials that used high dose intervention and trials that conducted on subjects with metabolic disorders. However, crocin supplementation did not significantly change FBG in trials that used low dose intervention. Meta-regression analysis indicated a linear relationship between the duration of intervention and significant change in FBG (pâ¯=â¯0.019). CONCLUSION: Results of this systematic review and meta-analysis study have shown that crocin supplementation can decrease significantly FBS and TC without any beneficial effects on TG, LDL-C, and HDL-C levels.
